STEAP (six-transmembrane epithelial antigen of the prostate) is a prostate-specific cell surface antigen, highly expressed in human prostate cancers. STEAP is unique among cell surface prostate antigens in its potential function as a channel or transport protein.
High expression of STEAP has been detected at all states of prostate cancer, and does not seem to be modulated by hormones. This property is particularly useful for managing hormone-refractory prostate cancer or antiandrogen therapy for advanced metastatic disease, and may make STEAP a suitable target for antibody therapy, cancer vaccine therapy, and small-molecule therapy.
Zymed’s prostate antibodies have been characterized for immunohistostaining of frozen and formalin-fixed, paraffin-embedded tissue sections, including STEAP, Androgen Receptor, PSMA, PSCA, PsAP, PSA, and PTEN antibodies.
Zymed Laboratories
(800) 847-4497; www.zymed.com
